1. Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial
- Author
-
P. Corona, Dolors Rodríguez-Pardo, Jose Antonio Iribarren, Miguel Ángel García-Viejo, Magdalena Femenias, María Del Carmen Pulido-Garcia, Laura Guío-Carrión, María Dolores González-Ripoll Navarro, María Dolores del Toro, Benito Almirante, Laura Soldevila-Boixader, Carles Pigrau, María Velasco-Arribas, Mayli Lung, Marta Fernández-Sampedro, and Rosa Escudero-Sánchez
- Subjects
musculoskeletal diseases ,Male ,0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Prosthesis-Related Infections ,Bacteriuria ,Arthroplasty, Replacement, Hip ,030106 microbiology ,Periprosthetic ,Fosfomycin-trometamol ,urologic and male genital diseases ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Primary outcome ,Fosfomycin ,Randomized controlled trial ,law ,Internal medicine ,Humans ,Medicine ,030212 general & internal medicine ,Tromethamine ,Asymptomatic Infections ,Asymptomatic bacteriuria ,Aged ,Aged, 80 and over ,business.industry ,Incidence (epidemiology) ,Hip hemiarthroplasty ,Mean age ,General Medicine ,Anti-Bacterial Agents ,Infectious Diseases ,Early-periprosthetic joint infection ,Cohort ,Female ,Joint Diseases ,business - Abstract
[Purpose] To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture., [Methods] Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB. Primary outcome: early-PJI after HHA., [Results] Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33–3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15–7.10]). [Conclusions] Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47., This work was supported by the Spanish Clinical Research Network (SCReN), co-finaced by the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, through the project PI15/02161 and by the Plan Nacional de I+D+i 2013-016 and ISCIIII, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003)-co-financed by European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 2014-2020.
- Published
- 2021